Shares of Danish medtech company Ambu A/S fell 16.2% on Thursday after the firm reported weaker-than-expected quarterly revenue and reduced its full-year organic growth outlook.
The stock dropped to DKK 65.7 during the session, nearing its 52-week low of DKK 56.3 and well below its peak of DKK 111.8. At midday, the shares were down DKK 13.9 at DKK 64.60, according to one ticker reference.
Ambu posted revenue of DKK 1.57 billion for the third quarter of its 2025/26 fiscal year, missing the consensus estimate of DKK 1.62 billion. Organic revenue growth guidance for the full year was lowered to approximately 10%, down from the prior range of 10% to 12%.
Earnings per share for the quarter fell short of analyst expectations, and the company significantly revised its full-year EPS forecast downward. Profit margins also contracted sharply year-over-year due to elevated expenses.
Growth in the anesthesia and patient monitoring segment slowed sharply, with organic growth expected to remain minimal for the year amid weaker-than-anticipated U.S. customer volumes. The endoscopy solutions segment showed more stability but did not fully offset the decline in the anesthesia business.
Analysts at Danske Bank maintained a "sell" rating on Ambu with a DKK 61 price target, while Danish analysts at AL Sydbank warned that a potential earnings miss could trigger increased volatility.
Competitive pressure is intensifying, with rivals Boston Scientific and Olympus expanding their single-use device portfolios. The broader market offered little support, as U.S. indices closed marginally lower and European medtech stocks lacked sector tailwinds.
